Loading…
← CockpitCompetitor Analysis › SPTX Seaport Therapeutics, Inc.Open in the cockpit ↗

Seaport Therapeutics, Inc.SPTXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage neuroscience biotech using a proprietary prodrug delivery platform for CNS drug candidates.

Momentum neutral 44
Mkt cap
$980M
US dollars, full cap
Free float
26%
of shares outstanding
$/day
$6.34M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-126.7 pp
WACC 20.0%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$18.31
1D+0.8%
1W-14.1%
1M-5.0%
3M-23.8%
6M+16.0%
YTDn/a
1Yn/a
ATR %8.1%
52w lowhigh35.5% off high

What Seaport Therapeutics does

Clinical-stage neuroscience biotech using a proprietary prodrug delivery platform for CNS drug candidates.

Where it sits in the supply chain

  • Pharmaceuticals
  • Clinical-stage biotech
  • CNS/neuroscience

Moat: none

Headquarters: Boston, Massachusetts, US · Employees: 54

Seaport Therapeutics at a glance

Size Seaport Therapeutics (SPTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $980M, the 2247th largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.31 on 18 Nov 2026.

Performance Over six months the shares gained 16.0%, against -14.5% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Capital Return on invested capital runs 126.7 points below its cost of capital (20.0% WACC).

Short interest Short interest is 7.0% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026SPTX 107Peer median 90
Six months, rebased to 100: Seaport Therapeutics against the median of its 20 peers (local-currency closes).

Seaport Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenue$0$0$0
Revenue growth———
Gross profit-$1.43M-$1.41M-$214,000
EBITDA-$149M-$85.9M-$52.2M
Net income-$139M-$74.9M-$46.9M
Free cash flow-$95.7M-$78.3M-$29.7M
Capital expenditure$25,000$356,000$113,000
Total debt$4.69M$5.08M$5.01M

Quarterly statements and history in the cockpit →

Seaport Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%PGHL600129688382AARTIPHARM456560055768871068875960511668809130029448872005603538300702002437300497SPTX6-month return →1-month return →
Up and to the right = strong over both horizons. Seaport Therapeutics is the large dot.

Seaport Therapeutics competitors and peer comparison

How Seaport Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Seaport Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureSPTXPeer medianRank in peer set
1-month return-5.0%-7.6%9th highest of 21
6-month return+16.0%-14.5%4th highest of 21
Distance from 52-week high-35.5%-36.6%11th highest of 21
ROIC minus cost of capital-126.7 pp-0.4 pplowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%6.3×5.6%+9.3%
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%1.3×n/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%75.0×6.5%-60.6%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%4.7×n/an/a
Nxera Pharma 4565.TJapan$974M+46%+24%14%5.4×17.7%+27.3%
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%1.4×2.3%+1.8%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%5.2×12.7%+19.4%
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%4.2×-2.0%+18.7%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%19.3×n/an/a
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%2.5×n/an/a
SAWAI 4887.TJapan$1.01B-18%+2%9%1.3×n/an/a
SSY 2005.HKHong Kong$948M+8%-4%12%2.2×2.3%-0.5%
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%0.9×-10.7%-7.0%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%2.0×17.6%+7.8%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%3.8×11.6%+4.9%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%2.3×4.3%+3.5%
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%2.8×7.7%-6.9%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%1.8×n/an/a
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%4.0×7.5%-4.5%

Questions

Which companies are Seaport Therapeutics's closest peers?
The cockpit's peer set: Procter & Gamble Health (PGHL.NS), Chongqing Taiji Industry (Group) (600129.SS), InventisBio (688382.SS), Aarti Pharmalabs (AARTIPHARM.NS), Nxera Pharma (4565.T), Jiangsu Kanion Pharmaceutical (600557.SS), Shanghai InnoStar Bio-tech (688710.SS), BeBetter Med (688759.SS).
How has Seaport Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +16.0% against -14.5% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.